Quick answers
- What is Erythromycin ethylsuccinate used for?
- The FDA-approved label (Ery-Ped, Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), December 16, 2023) says: “To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Erythromycin ethylsuccinate have a boxed warning?
- No. None of the 15 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Erythromycin ethylsuccinate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Erythromycin ethylsuccinate been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Erythromycin ethylsuccinate?
- 10 companies list prescription products of Erythromycin ethylsuccinate in the FDA NDC Directory, including Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), Amneal Pharmaceuticals NY LLC and ANI Pharmaceuticals, Inc..
What Erythromycin ethylsuccinate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. …
— FDA label: Ery-Ped, Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), effective December 16, 2023. Read the full label on DailyMed →
The FDA has 15 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 15 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Suspension · Granule, for suspension · For suspension · Tablet |
|---|---|
| Route | Oral |
| Prescription products | 26 in the FDA NDC Directory |
| Brand names | Ery-Ped, E.E.S 400, E.E.S |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| erythromycin ethylsuccinate 200 mg/5 mL granule, for suspension | Generic | $0.9787–$1.49 per mL 4 packages, lowest to highest |
| erythromycin ethylsuccinate 200 mg/5 mL suspension | Generic | $0.9787 per mL |
| erythromycin ethylsuccinate 400 mg/5 mL granule, for suspension | Generic | $1.67 per mL |
| erythromycin ethylsuccinate 400 mg/5 mL suspension | Generic | $1.67 per mL |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)6 products
- Amneal Pharmaceuticals NY LLC4 products
- ANI Pharmaceuticals, Inc.3 products
- Nivagen Pharmaceuticals, Inc.2 products
- Kanchan Healthcare Inc2 products
- Wilshire Pharmaceuticals2 products
- Cadila Pharmaceuticals Limited2 products
- Bryant Ranch Prepack2 products
- Wilshire Pharmaceuticals, Inc.2 products
- Remedyrepack Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA050207 E.E.S., ERYPED | Carnegie | April 2, 1965 | 18, latest April 23, 2018 2018: Labeling · 2017: Labeling · 2012: Labeling |
Generic approvals (5)
- ANDA061904Carnegie · March 3, 1975
- ANDA062055Ani Pharms · November 27, 1978
- ANDA061905Pharmobedient · August 12, 1982
- ANDA211204Amneal Pharms · November 1, 2019
- ANDA216212Cadila Pharms Ltd · November 21, 2022
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Ery-Ped, Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals), effective December 16, 2023; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →